Yüklüyor......
Clinical role of brexpiprazole in depression and schizophrenia
Brexpiprazole, a serotonin–dopamine activity modulator, is the second D(2) partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D(2) receptor and h...
Kaydedildi:
| Yayımlandı: | Ther Clin Risk Manag |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5354524/ https://ncbi.nlm.nih.gov/pubmed/28331332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S94060 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|